620 related articles for article (PubMed ID: 25581683)
21. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
22. Targeting class I histone deacetylases in cancer therapy.
Delcuve GP; Khan DH; Davie JR
Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
[TBL] [Abstract][Full Text] [Related]
23. Inside HDAC with HDAC inhibitors.
Bertrand P
Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
Giannini G; Cabri W; Fattorusso C; Rodriquez M
Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
[TBL] [Abstract][Full Text] [Related]
25. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
26. Peptide based macrocycles: selective histone deacetylase inhibitors with antiproliferative activity.
Rajak H; Singh A; Dewangan PK; Patel V; Jain DK; Tiwari SK; Veerasamy R; Sharma PC
Curr Med Chem; 2013; 20(14):1887-903. PubMed ID: 23409715
[TBL] [Abstract][Full Text] [Related]
27. Multimodal HDAC Inhibitors with Improved Anticancer Activity.
Schobert R; Biersack B
Curr Cancer Drug Targets; 2018; 18(1):39-56. PubMed ID: 28176653
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
[TBL] [Abstract][Full Text] [Related]
29. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
[TBL] [Abstract][Full Text] [Related]
30. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
31. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
Liu T; Wan Y; Xiao Y; Xia C; Duan G
J Med Chem; 2020 Sep; 63(17):8977-9002. PubMed ID: 32320239
[TBL] [Abstract][Full Text] [Related]
32. Drugging the HDAC6-HSP90 interplay in malignant cells.
Krämer OH; Mahboobi S; Sellmer A
Trends Pharmacol Sci; 2014 Oct; 35(10):501-9. PubMed ID: 25234862
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
34. Strategies in developing promising histone deacetylase inhibitors.
Zhang L; Fang H; Xu W
Med Res Rev; 2010 Jul; 30(4):585-602. PubMed ID: 19634125
[TBL] [Abstract][Full Text] [Related]
35. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update.
Sultana F; Manasa KL; Shaik SP; Bonam SR; Kamal A
Curr Med Chem; 2019; 26(40):7212-7280. PubMed ID: 29852860
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Mottamal M; Zheng S; Huang TL; Wang G
Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
[TBL] [Abstract][Full Text] [Related]
37. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
Zhao C; Dong H; Xu Q; Zhang Y
Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
[No Abstract] [Full Text] [Related]
39. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
[TBL] [Abstract][Full Text] [Related]
40. The potential of histone deacetylase inhibitors in lung cancer.
Aparicio A
Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
